Abstract
Cell binding and Fab-mediated functionality of FcγRIIIa-enhanced antibodies. A, Binding of anti-HER2 and anti-FRα IgG variants (0.03–10 µg/mL) to NK cells evaluated by flow cytometry (n = 4). B and C, Binding of monomeric anti-HER2 IgG variants (0.0001–10 µg/mL) to HER2-expressing (SKBR3 and HCC1954) or nonexpressing (CAL51) cells (n = 3–6; B) or to FRα-expressing (CAL51 and T47D) or nonexpressing (SKBR3) cells (n = 3–6; C). D, Impact of antibodies on proliferation detected by live-cell imaging (Incucyte; n = 3). Representative images of cells treated with 10 μg/mL anti-HER2 antibody variants for 5 days. Scale bar, 100 μm. MFI, median fluorescence intensity.